| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparative study of the immunosuppressive activityof ciclosporin (CSP) and dexamethasone (DM) in patients with bronchial asthma
|
|
|
1992
|
5 |
SA |
p. xxxix-
1 p.
|
artikel
|
| 2 |
A multicenter randomized study comparing cyclosporin-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia
|
Gluckman, Eliane
|
|
1992
|
5 |
SA |
p. 271-275
5 p.
|
artikel
|
| 3 |
Antibodies to Basic Myelin Protein (BMP) in Multiple Sclerosis (MS): The correlation with the severity of the disease and Methypred therapy
|
Zavalishin, I.A.
|
|
1992
|
5 |
SA |
p. xxiii-
1 p.
|
artikel
|
| 4 |
Antibody and T cell responses to mycobacterial proteinsin rheumatoid arthritis and juvenile rheumatoid arthritis: Evidence for increased usage of T cell receptor Vβ14 and Vβ18 families in the rheumatoid08080108 V3 inflammation
|
Førre, Ø
|
|
1992
|
5 |
SA |
p. xxxii-
1 p.
|
artikel
|
| 5 |
Anti-CD4 monoclonal antibodies in psoriasis
|
Herzog, C.H.
|
|
1992
|
5 |
SA |
p. xxvi-
1 p.
|
artikel
|
| 6 |
Anti-proteinuric effect of cyclosporin (CsA) in anti-GBM nephritis in the mouse
|
|
|
1992
|
5 |
SA |
p. xxxix-
1 p.
|
artikel
|
| 7 |
Are endogenous retroviruses involved in humanautoimmune disease?
|
Talal, Norman
|
|
1992
|
5 |
SA |
p. 61-66
6 p.
|
artikel
|
| 8 |
Binding of T lymphocytes to fibronectin in rheumatoidarthritis
|
|
|
1992
|
5 |
SA |
p. xxxv-
1 p.
|
artikel
|
| 9 |
Blood Brain Barrier (BBB) permeability during Chronic RelapsingExperimental Allergic Encephalomyelitis (CREAE) in the mouse
|
Allen, S.J.
|
|
1992
|
5 |
SA |
p. xxi-
1 p.
|
artikel
|
| 10 |
Calcitonin prevents cyclosporin-A induced bone loss
|
Stein, B
|
|
1992
|
5 |
SA |
p. xxxiv-
1 p.
|
artikel
|
| 11 |
c-AMP binding to protein kinase in erythrocyte membranes ofpsoriatic patients under therapy with cyclosporin A
|
|
|
1992
|
5 |
SA |
p. xxviii-
1 p.
|
artikel
|
| 12 |
Central MHC genes may regulate autoimmune responses in myasthenia gravis and insulin dependent diabetes mellitus
|
Dawkins, R.L.
|
|
1992
|
5 |
SA |
p. xvi-
1 p.
|
artikel
|
| 13 |
Changes in renal biopsies during low dosage cyclosporin A
|
Hansen, H.E.
|
|
1992
|
5 |
SA |
p. xlii-
1 p.
|
artikel
|
| 14 |
Characterisation of early autoreactive T cells inNOD mice
|
Burtles, S
|
|
1992
|
5 |
SA |
p. xxxii-
1 p.
|
artikel
|
| 15 |
Ciclosporin A in endogenous posterior uveitis
|
|
|
1992
|
5 |
SA |
p. v-
1 p.
|
artikel
|
| 16 |
Ciclosporin A versus Azathioprine in Multiple Sclerosis—Sevenyears follow-up and longterm side effects
|
|
|
1992
|
5 |
SA |
p. xxiv-
1 p.
|
artikel
|
| 17 |
Ciclosporine (CsA) vs Cyclophosphamide (Cyc) in children with steroid-dependentfrequently relapsing nephrotic syndrome (SD/FR NS): Evaluation of growth 08320215 V3
|
Edefonti, A.
|
|
1992
|
5 |
SA |
p. xl-
1 p.
|
artikel
|
| 18 |
Ciclosporin for psoriasis
|
|
|
1992
|
5 |
SA |
p. x-
1 p.
|
artikel
|
| 19 |
Combined ciclosporin A/steroid/methotrexate treatment of 23 patients with rheumatoid arthritis
|
Miescher, P.A.
|
|
1992
|
5 |
SA |
p. xx-
1 p.
|
artikel
|
| 20 |
Combined ciclosporin A/steroid treatment for SLE patients
|
Favre, H
|
|
1992
|
5 |
SA |
p. viii-
1 p.
|
artikel
|
| 21 |
Comparison of ciclosporin A (CyA) and etretinate (Etr) for severe diffuse plaque formpsoriasis: A multicenter randomized open study
|
Finzi, A.F.
|
|
1992
|
5 |
SA |
p. xi-
1 p.
|
artikel
|
| 22 |
Comparison of Cyclosporine (CsA) and Azathioprine (Aza) for rheumatoid arthritis: Amulticenter, randomized, double-blind study
|
Mathieu, A.
|
|
1992
|
5 |
SA |
p. xx-
1 p.
|
artikel
|
| 23 |
Comparison of the inhibitory effects of immunosuppressivedrugs cyclosporin A, tetranactine and didemnin B on human T cell responses in vitro
|
Teunissen, M.B.M.
|
|
1992
|
5 |
SA |
p. xxvi-
1 p.
|
artikel
|
| 24 |
Continuation of insulin therapy increases β-cell 08080 recovery in type I diabetes treated with low dose ciclosporin
|
|
|
1992
|
5 |
SA |
p. xxx-
1 p.
|
artikel
|
| 25 |
Cyclosporin A (CsA) and its less nephrotoxic homologue,cyclosporin G (CsG), directly inhibit normal and ichthyotic keratinocyte growth in culture
|
|
|
1992
|
5 |
SA |
p. xxv-
1 p.
|
artikel
|
| 26 |
Cyclosporin A [CyA] inhibits airway eosinophilia inallergic guinea-pigs
|
|
|
1992
|
5 |
SA |
p. xxxvii-
1 p.
|
artikel
|
| 27 |
Cyclosporin A in aspirin-induced asthma
|
Herzog, C.H.
|
|
1992
|
5 |
SA |
p. xxxviii-
1 p.
|
artikel
|
| 28 |
Cyclosporin A in asthma therapy: a pharmacological rationale
|
Morley, J.
|
|
1992
|
5 |
SA |
p. 265-269
5 p.
|
artikel
|
| 29 |
Cyclosporin A (Sandimmune R) in psoriasis: Interim results of a multicenter dose-finding study in severe plaque form psoriasis
|
|
|
1992
|
5 |
SA |
p. ix-
1 p.
|
artikel
|
| 30 |
Cyclosporin A (Sandimmun®) in chronic severe steroid-dependent asthma
|
|
|
1992
|
5 |
SA |
p. xxxvii-
1 p.
|
artikel
|
| 31 |
Cyclosporin (CS) and the clinical course of steroid-dependentasthma
|
|
|
1992
|
5 |
SA |
p. xxxviii-
1 p.
|
artikel
|
| 32 |
Cyclosporine as a disease modifier in rheumatoid arthritis
|
Førre, Ø.
|
|
1992
|
5 |
SA |
p. xix-
1 p.
|
artikel
|
| 33 |
Cyclosporine A vs. Azathioprine in the treatment of RA — Results of a controlled multicenter double-blind study
|
|
|
1992
|
5 |
SA |
p. xix-
1 p.
|
artikel
|
| 34 |
Cyclosporine in nephrotic syndrome: The Japanese experience
|
Nagasawa, T.
|
|
1992
|
5 |
SA |
p. xxxvi-
1 p.
|
artikel
|
| 35 |
Cyclosporine in the treatment of severe refractory ulcerativecolitis
|
|
|
1992
|
5 |
SA |
p. ii-
1 p.
|
artikel
|
| 36 |
Cyclosporine in ulcerative colitis complications
|
Giacomelli, R
|
|
1992
|
5 |
SA |
p. iii-
1 p.
|
artikel
|
| 37 |
Cyclosporin for palmo-plantar pustulosis
|
Reitamo, S
|
|
1992
|
5 |
SA |
p. xi-
1 p.
|
artikel
|
| 38 |
Cyclosporin for palmoplantar pustulosis
|
Reitamo, Sakari
|
|
1992
|
5 |
SA |
p. 285-287
3 p.
|
artikel
|
| 39 |
Cyclosporin for severe idiopathic membranous nephropathy
|
Rostoker, G.
|
|
1992
|
5 |
SA |
p. xli-
1 p.
|
artikel
|
| 40 |
Cyclosporin in severe atopic dermatitis: A multicentre double-blind trial
|
Allen, B.R.
|
|
1992
|
5 |
SA |
p. vii-
1 p.
|
artikel
|
| 41 |
Cyclosporin in the treatment of rheumatoid arthritis
|
Tugwell, Peter
|
|
1992
|
5 |
SA |
p. 231-240
10 p.
|
artikel
|
| 42 |
Cyclosporin monitoring: Its role in autoimmune indications
|
Holt, David W.
|
|
1992
|
5 |
SA |
p. 177-182
6 p.
|
artikel
|
| 43 |
Cyclosporin (Sandimmun(R)) in chronic endogenous Uveitis
|
Klein, S.
|
|
1992
|
5 |
SA |
p. v-
1 p.
|
artikel
|
| 44 |
Definition of the cyclosporin-sensitive event in T lymphocyteactivation
|
|
|
1992
|
5 |
SA |
p. viii-
1 p.
|
artikel
|
| 45 |
Determinants of prolonged (> 1 year) Non-Insulin-Receiving (NIR) remission of IDDM during cyclosporine A (CsA treatment)
|
Hramiak, I.
|
|
1992
|
5 |
SA |
p. xxix-
1 p.
|
artikel
|
| 46 |
Dose-dependent corneal storage of ciclosporin A (CSA)after topical application
|
|
|
1992
|
5 |
SA |
p. xii-
1 p.
|
artikel
|
| 47 |
Editorial Board
|
|
|
1992
|
5 |
SA |
p. CO2-
1 p.
|
artikel
|
| 48 |
Effect of cyclosporin on the regulation of Ia expression in theskin
|
|
|
1992
|
5 |
SA |
p. xxix-
1 p.
|
artikel
|
| 49 |
Effect of Sandimmune on radiometric and biochemicalparameters of bone turnover in normal rats
|
|
|
1992
|
5 |
SA |
p. xxxiv-
1 p.
|
artikel
|
| 50 |
Effects of cyclosporin on glomerular barrier function in nephrotic syndrome
|
|
|
1992
|
5 |
SA |
p. xl-
1 p.
|
artikel
|
| 51 |
Effects of the treatment with cyclosporine in children with Type 1 insulin-dependent diabetes of recent onset: Results of a multicentre trial
|
|
|
1992
|
5 |
SA |
p. xxx-
1 p.
|
artikel
|
| 52 |
Extension of indications of immunosuppression in inflammatory bowel disease
|
Riis, Povl
|
|
1992
|
5 |
SA |
p. 289-291
3 p.
|
artikel
|
| 53 |
Generation of mutant mice lacking surfaceexpression of CD4 or CD8 by gene targeting
|
Mak, Tak W.
|
|
1992
|
5 |
SA |
p. 55-59
5 p.
|
artikel
|
| 54 |
HLA class II disease associations: Molecular basis
|
Charron, Dominique
|
|
1992
|
5 |
SA |
p. 45-53
9 p.
|
artikel
|
| 55 |
HLA oligotyping of DR4 haplotypes in diabetes of typeIa or associated with polyendocrinopathies
|
|
|
1992
|
5 |
SA |
p. xxxi-
1 p.
|
artikel
|
| 56 |
Idiotypic vaccination of experimental autoimmune uveoretinitis
|
de Kozak, Y.
|
|
1992
|
5 |
SA |
p. xxv-
1 p.
|
artikel
|
| 57 |
Immunointervention in autoimmune diseasesfrom cellular selectivity to autoantigen specificity
|
Bach, Jean-François
|
|
1992
|
5 |
SA |
p. 3-10
8 p.
|
artikel
|
| 58 |
Immunointervention in primary biliary cirrhosis: an overview
|
Bray, Gary P.
|
|
1992
|
5 |
SA |
p. 293-300
8 p.
|
artikel
|
| 59 |
Immunointervention with cyclosporin A in autoimmune neurological disorders
|
Tindall, Richard S.A.
|
|
1992
|
5 |
SA |
p. 301-313
13 p.
|
artikel
|
| 60 |
Immunological follow up of 13 patients with rheumatoid arthritis treated by anti-T CD4+ monoclonal antibodies
|
Racadot, E.
|
|
1992
|
5 |
SA |
p. xvi-
1 p.
|
artikel
|
| 61 |
Immunologically specific treatment ofspontaneous insulin-dependent diabetes mellitus of NOD mice
|
Cohen, Irun R.
|
|
1992
|
5 |
SA |
p. 227-230
4 p.
|
artikel
|
| 62 |
Immunological monitoring in organtransplantation and autoimmune disease
|
Keown, Paul A.
|
|
1992
|
5 |
SA |
p. 343-348
6 p.
|
artikel
|
| 63 |
Immunosuppression with OKT3 in multiplesclerosis: Follow-up after three years
|
|
|
1992
|
5 |
SA |
p. xxiv-
1 p.
|
artikel
|
| 64 |
Immunosuppressive treatment of aplastic anemia:Comparative trial evaluating antilymphocyte globulin versus antilymphocyte globulin and ciclosporin A
|
Schrezenmeier, H.
|
|
1992
|
5 |
SA |
p. i-
1 p.
|
artikel
|
| 65 |
Inhibition of T cell activation by MHC blockade: A possible strategy for immunointervention in autoimmune diseases
|
Adorini, Luciano
|
|
1992
|
5 |
SA |
p. 73-81
9 p.
|
artikel
|
| 66 |
In situ preferential usage of Va8 T-cell receptor gene segments in a patient with bullous pemphigoid
|
Michalaki, H
|
|
1992
|
5 |
SA |
p. xxxvi-
1 p.
|
artikel
|
| 67 |
Insulin autoimmunity: the rate limiting factor inpre-type I diabetes
|
Eisenbarth, George S.
|
|
1992
|
5 |
SA |
p. 241-246
6 p.
|
artikel
|
| 68 |
Interleukin-6 and its receptor in autoimmunity
|
Kishimoto, Tadamitsu
|
|
1992
|
5 |
SA |
p. 123-132
10 p.
|
artikel
|
| 69 |
Introduction
|
|
|
1992
|
5 |
SA |
p. 1-
1 p.
|
artikel
|
| 70 |
Limited T cell receptor V beta chain usage in the BB rat
|
Bellgrau, Donald
|
|
1992
|
5 |
SA |
p. xxxi-
1 p.
|
artikel
|
| 71 |
Local Cyclosporin-A treatment in infiltrative endocrine ophthalmopathy
|
Kálmán, K.
|
|
1992
|
5 |
SA |
p. xv-
1 p.
|
artikel
|
| 72 |
Low dose cyclosporine in psoriasis: Two strategies
|
Dubertret, L.
|
|
1992
|
5 |
SA |
p. ix-
1 p.
|
artikel
|
| 73 |
Low-dose cyclosporin therapy of ocular inflammation: Preliminary report of a long-term follow-up study
|
Towler, Hamish M.A.
|
|
1992
|
5 |
SA |
p. 259-264
6 p.
|
artikel
|
| 74 |
Low dose cyclosporin treatment of ocular inflammation: Long term follow up study
|
|
|
1992
|
5 |
SA |
p. iii-
1 p.
|
artikel
|
| 75 |
Low-dose of ciclosporin treatment for Behcet's disease with active ocular inflammation
|
Hayashi, K.
|
|
1992
|
5 |
SA |
p. iv-
1 p.
|
artikel
|
| 76 |
Malignancy in autoimmune diseases
|
Kinlen, L.J.
|
|
1992
|
5 |
SA |
p. 363-371
9 p.
|
artikel
|
| 77 |
MHC-binding peptides for immunotherapy ofexperimental autoimmune disease
|
Wraith, David C.
|
|
1992
|
5 |
SA |
p. 103-113
11 p.
|
artikel
|
| 78 |
Molecular mechanisms of immunosuppression
|
Baumann, Götz
|
|
1992
|
5 |
SA |
p. 67-72
6 p.
|
artikel
|
| 79 |
Molecular mode of action of cyclosporin and FK506in human thymocytes
|
Reem, Gabrielle H.
|
|
1992
|
5 |
SA |
p. 159-165
7 p.
|
artikel
|
| 80 |
Monoclonal antibodies as agents to reinducetolerance in autoimmunity
|
Waldmann, Herman
|
|
1992
|
5 |
SA |
p. 93-102
10 p.
|
artikel
|
| 81 |
Penetration of ciclosporin eyedrops into human oculartissue
|
|
|
1992
|
5 |
SA |
p. xiii-
1 p.
|
artikel
|
| 82 |
Pharmacokinetic strategies for cyclosporin therapy in organ transplantation
|
Kahan, Barry D.
|
|
1992
|
5 |
SA |
p. 333-341
9 p.
|
artikel
|
| 83 |
Phase I safety and tolerability studies of 2% cyclosporine (CY)(Sandimmune®) ophthalmic ointment
|
|
|
1992
|
5 |
SA |
p. xiii-
1 p.
|
artikel
|
| 84 |
Pilot study of combination anti IL2R MC antibody-low dose of cyclosporin A in recently diagnosed type 1 diabetes
|
Vialettes, B
|
|
1992
|
5 |
SA |
p. xviii-
1 p.
|
artikel
|
| 85 |
Post-thymic tolerance to self antigens
|
Miller, Jacques F.A.P.
|
|
1992
|
5 |
SA |
p. 27-35
9 p.
|
artikel
|
| 86 |
Production of osteoclast activating factors by human autologous bone cell — T lymphocyte mixed cultures is blocked by Cyclosporin A
|
|
|
1992
|
5 |
SA |
p. xxxiii-
1 p.
|
artikel
|
| 87 |
Protection against experimental encephalomyelitis: Idiotypic autoregulation induced by a non-encephalitogenic T cell clone expressing a cross-reactive T cell receptor V gene
|
|
|
1992
|
5 |
SA |
p. xxiii-
1 p.
|
artikel
|
| 88 |
Psoriasis: Immunopathology and long-term treatment with cyclosporin
|
Fry, Lionel
|
|
1992
|
5 |
SA |
p. 277-283
7 p.
|
artikel
|
| 89 |
Renal function after longterm treatment for psoriasis
|
Powles, A.V.
|
|
1992
|
5 |
SA |
p. xliii-
1 p.
|
artikel
|
| 90 |
Renal function in patients with autoimmune diseases treatedwith cyclosporine
|
|
|
1992
|
5 |
SA |
p. xliii-
1 p.
|
artikel
|
| 91 |
Renal function in patients with Rheumatoid Arthritis (RA)treated with Cyclosporine A (CYA) and Non-Steroidal Antiinflammatory Drugs (NSAIDs)
|
|
|
1992
|
5 |
SA |
p. xxi-
1 p.
|
artikel
|
| 92 |
Serial kidney biopsies in patients with nephrotic syndrome treated with ciclosporin A (CiA)
|
Sieberth, H.G.
|
|
1992
|
5 |
SA |
p. xlii-
1 p.
|
artikel
|
| 93 |
Serial kidney biopsies in patients with nephroticsyndrome treated with cyclosporin
|
Sieberth, Heinz-Günter
|
|
1992
|
5 |
SA |
p. 355-361
7 p.
|
artikel
|
| 94 |
Sjoegren's syndrome: Treatment with ciclosporin A (CsA)
|
Leuenberger, P.M.
|
|
1992
|
5 |
SA |
p. vi-
1 p.
|
artikel
|
| 95 |
Soluble interleukin-2 receptor and CD25+ cells in psoriasis: Effects of cyclosporin A and PUVA therapy
|
|
|
1992
|
5 |
SA |
p. xxvii-
1 p.
|
artikel
|
| 96 |
Specific and non-specific autoreactive immunity
|
Möller, Erna
|
|
1992
|
5 |
SA |
p. 37-44
8 p.
|
artikel
|
| 97 |
Spontaneous arthritis in DBA/1 mice08080108 V2
|
|
|
1992
|
5 |
SA |
p. xxxv-
1 p.
|
artikel
|
| 98 |
SRC-related proto-oncogenes and transcriptionfactors in primary human T cells: Modulation by cyclosporin A and FK506
|
Granelli-Piperno, Angela
|
|
1992
|
5 |
SA |
p. 145-158
14 p.
|
artikel
|
| 99 |
Studies on the role of tumor necrosis factor inmurine and human autoimmunity
|
Jacob, Chaim O.
|
|
1992
|
5 |
SA |
p. 133-143
11 p.
|
artikel
|
| 100 |
Systemic absortion of ciclosporin A (CSA) following topicalapplication of 2% eyedrop in the rabbit eye
|
|
|
1992
|
5 |
SA |
p. xii-
1 p.
|
artikel
|
| 101 |
T cell activation and antigen presentation inhuman thyroid autoimmunity
|
Feldmann, Marc
|
|
1992
|
5 |
SA |
p. 115-121
7 p.
|
artikel
|
| 102 |
T cell receptor peptide therapy for autoimmune disease
|
Vandenbark, Arthur A.
|
|
1992
|
5 |
SA |
p. 83-92
10 p.
|
artikel
|
| 103 |
The case for early intervention in rheumatoidarthritis
|
Pincus, Theodore
|
|
1992
|
5 |
SA |
p. 209-226
18 p.
|
artikel
|
| 104 |
The effect of CsA and IFN-γ on the growth, phenotype and cytokine production of keratinocytes
|
|
|
1992
|
5 |
SA |
p. xxvii-
1 p.
|
artikel
|
| 105 |
The effect of cyclosporin A on cytokine gene expression in cultured human trabecular osteoblast-like cells using PCR
|
Graveley, R.M.
|
|
1992
|
5 |
SA |
p. xxxiii-
1 p.
|
artikel
|
| 106 |
The effect of cyclosporine A on experimental SLE
|
Shoenfeld, Y.
|
|
1992
|
5 |
SA |
p. vii-
1 p.
|
artikel
|
| 107 |
The effect of cyclosporin on renal function
|
Mason, June
|
|
1992
|
5 |
SA |
p. 349-354
6 p.
|
artikel
|
| 108 |
The effects of cyclosporin A on non-T cell components of the immune system
|
Thomson, A.W.
|
|
1992
|
5 |
SA |
p. 167-176
10 p.
|
artikel
|
| 109 |
The efficacy of cyclosporine (CSA) is dose-dependent innephrotic children with hypercholesterolemia
|
|
|
1992
|
5 |
SA |
p. xli-
1 p.
|
artikel
|
| 110 |
The efficacy of cyclosporine in the treatment of Crohn's perianal and fistulous disease
|
|
|
1992
|
5 |
SA |
p. ii-
1 p.
|
artikel
|
| 111 |
The efficacy of low-dose cyclosporine a therapy in psoriasis in comparison to etretinate
|
|
|
1992
|
5 |
SA |
p. x-
1 p.
|
artikel
|
| 112 |
The expanding use of immunosuppression in thetreatment of non-infectious ocular disease
|
Nussenblatt, Robert
|
|
1992
|
5 |
SA |
p. 247-257
11 p.
|
artikel
|
| 113 |
The forces driving autoimmune disease
|
Roitt, Ivan M.
|
|
1992
|
5 |
SA |
p. 11-26
16 p.
|
artikel
|
| 114 |
The influence of SANDIMMUN (CYA) on the antigen-presenting mechanism in lesional epidermis of psoriasis, les, led and lichen planus. The role of langerhans cells
|
Miori, L.
|
|
1992
|
5 |
SA |
p. xxviii-
1 p.
|
artikel
|
| 115 |
The optimal use of cyclosporin A in autoimmune diseases
|
Feutren, Gilles
|
|
1992
|
5 |
SA |
p. 183-195
13 p.
|
artikel
|
| 116 |
Therapeutic control of Chronic Relapsing Experimental Allergic Encephalomyelitis (CREAE) in the Biozzi mouse
|
|
|
1992
|
5 |
SA |
p. xxii-
1 p.
|
artikel
|
| 117 |
The role CD8+ T cells in the immuno-modulation of Experimental Autoimmune Encepalomyelitis(EAE). Analysis in PL/J mutant mice having no 08060608 V3 CD8+ T cells
|
|
|
1992
|
5 |
SA |
p. xxii-
1 p.
|
artikel
|
| 118 |
The usefulness of ciclosporin (Sandimmun) in the treatment ofBehcet's syndrome: Preliminary results of an open study
|
Pacor, M.L.
|
|
1992
|
5 |
SA |
p. iv-
1 p.
|
artikel
|
| 119 |
The use of topical cyclosporin in human keratoconjunctivitis sicca
|
|
|
1992
|
5 |
SA |
p. xiv-
1 p.
|
artikel
|
| 120 |
Timing of immunosuppression in the natural history of autoimmune disease
|
Steinberg, Alfred D.
|
|
1992
|
5 |
SA |
p. 197-203
7 p.
|
artikel
|
| 121 |
Topical cyclosporine a in the treatment of vernalconjunctivitis
|
|
|
1992
|
5 |
SA |
p. xiv-
1 p.
|
artikel
|
| 122 |
Topical Cyclosportine-A in the treatment of external immunologically mediated ophthalmological diseases
|
Secchi, A.G.
|
|
1992
|
5 |
SA |
p. xv-
1 p.
|
artikel
|
| 123 |
Towards peptide immunotherapy in rheumatoidarthritis: Competitor-modulator concept
|
Wauben, Marca H.M.
|
|
1992
|
5 |
SA |
p. 205-208
4 p.
|
artikel
|
| 124 |
Treatment of idiopathic nephrotic syndrome withcyclosporin in children. Preliminary results of growth data in long term use
|
Broyer, Michel
|
|
1992
|
5 |
SA |
p. 325-331
7 p.
|
artikel
|
| 125 |
Treatment of Mooren's ulcer with cyclosporine: Report of fivecases
|
|
|
1992
|
5 |
SA |
p. vi-
1 p.
|
artikel
|
| 126 |
Treatment of Rheumatoid Arthritis (RA) with monoclonal anti-CD4antibodies. I—Clinical results
|
|
|
1992
|
5 |
SA |
p. xvii-
1 p.
|
artikel
|
| 127 |
Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody. II.—Immunological results
|
|
|
1992
|
5 |
SA |
p. xvii-
1 p.
|
artikel
|
| 128 |
Treatment of severe systemic lupus erythematosus with monoclonal anti-CD4 antibody reduces anti-DNA-production in vitro
|
Hiepe, F.
|
|
1992
|
5 |
SA |
p. xviii-
1 p.
|
artikel
|
| 129 |
Treatment of the nephrotic syndrome with cyclosporin A
|
Ponticelli, Claudio
|
|
1992
|
5 |
SA |
p. 315-324
10 p.
|
artikel
|
| 130 |
Use of cyclosporine A for the treatment of severe aplastic anemia
|
|
|
1992
|
5 |
SA |
p. i-
1 p.
|
artikel
|
Tijdschrift beschrijving